These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 22941024)

  • 1. Targeted agents and systemic therapy in hepatocellular carcinoma.
    Ang C; O'Reilly EM; Abou-Alfa GK
    Recent Results Cancer Res; 2013; 190():225-46. PubMed ID: 22941024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug insight: VEGF as a therapeutic target for breast cancer.
    Schneider BP; Sledge GW
    Nat Clin Pract Oncol; 2007 Mar; 4(3):181-9. PubMed ID: 17327858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].
    Hagymási K; Tulassay Z
    Orv Hetil; 2010 Oct; 151(43):1763-8. PubMed ID: 20940115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of hepatocellular carcinoma: beyond sorafenib.
    Chan SL; Mok T; Ma BB
    Curr Oncol Rep; 2012 Jun; 14(3):257-66. PubMed ID: 22434314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapy in advanced non-small-cell lung cancer.
    Gettinger S
    Semin Respir Crit Care Med; 2008 Jun; 29(3):291-301. PubMed ID: 18506667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma.
    Zhu AX
    Cancer; 2008 Jan; 112(2):250-9. PubMed ID: 18041064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of systemic therapy of advanced hepatocellular carcinoma.
    Yau T; Chan P; Epstein R; Poon RT
    World J Gastroenterol; 2008 Nov; 14(42):6437-41. PubMed ID: 19030192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib: where do we go from here?
    Siegel AB; Olsen SK; Magun A; Brown RS
    Hepatology; 2010 Jul; 52(1):360-9. PubMed ID: 20578152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma?
    Oseini AM; Roberts LR
    Expert Opin Ther Targets; 2009 Apr; 13(4):443-54. PubMed ID: 19335066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Yang Y; Jiang H; Gao H; Kong J; Zhang P; Hu S; Shi B; Zhang P; Yao M; Li Z
    Neoplasia; 2012 Jun; 14(6):509-18. PubMed ID: 22787432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma.
    Sieghart W; Pinter M; Dauser B; Rohr-Udilova N; Piguet AC; Prager G; Hayden H; Dienes HP; Dufour JF; Peck-Radosavljevic M
    J Hepatol; 2012 Sep; 57(3):592-9. PubMed ID: 22634341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms of sorafenib action in liver cancer cells.
    Cervello M; Bachvarov D; Lampiasi N; Cusimano A; Azzolina A; McCubrey JA; Montalto G
    Cell Cycle; 2012 Aug; 11(15):2843-55. PubMed ID: 22801548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular therapy for the treatment of hepatocellular carcinoma.
    Greten TF; Korangy F; Manns MP; Malek NP
    Br J Cancer; 2009 Jan; 100(1):19-23. PubMed ID: 19018262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced hepatocellular carcinoma. Review of targeted molecular drugs.
    Alves RC; Alves D; Guz B; Matos C; Viana M; Harriz M; Terrabuio D; Kondo M; Gampel O; Polletti P
    Ann Hepatol; 2011; 10(1):21-7. PubMed ID: 21301005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives.
    Shen YC; Hsu C; Cheng AL
    J Gastroenterol; 2010 Aug; 45(8):794-807. PubMed ID: 20567987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC).
    Pazo-Cid RA; Lanzuela M; Esquerdo G; Pérez-Gracia JL; Antón A; Amigo G; Trufero JM; García-Otín AL; Martín-Duque P
    Clin Transl Oncol; 2012 Aug; 14(8):564-74. PubMed ID: 22855137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapies in hepatocellular carcinoma.
    Bronte F; Bronte G; Cusenza S; Fiorentino E; Rolfo C; Cicero G; Bronte E; Di Marco V; Firenze A; Angarano G; Fontana T; Russo A
    Curr Med Chem; 2014; 21(8):966-74. PubMed ID: 23992323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.
    Matsuda Y; Fukumoto M
    Med Mol Morphol; 2011 Dec; 44(4):183-9. PubMed ID: 22179180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib.
    Wich C; Agaimy A; Strobel D; Wissniowski TT; Hartmann A; Ocker M
    World J Gastroenterol; 2010 Jul; 16(28):3592-6. PubMed ID: 20653070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Targeted therapies in hepatocellular carcinoma].
    Bouattour M; Marijon H; Dreyer C; Faivre S; Raymond E
    Presse Med; 2010; 39(7-8):753-64. PubMed ID: 20378303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.